title: [Cardiovascular alterations associated with doping].
abstract: Doping -the abuse of anabolic-androgenic steroids in particular- is widespread in amateur and recreational sports and does not solely represent a problem of professional sports. Excessive overdose of anabolic steroids is well documented in bodybuilding or powerlifting leading to significant side effects. Cardiovascular damages are most relevant next to adverse endocrine effects.Clinical cases as well as forensic investigations of fatalities or steroid consumption in connection with trafficking of doping agents provide only anecdotal evidence of correlations between side effects and substance abuse. Analytical verification and self-declarations of steroid users have repeatedly confirmed the presumption of weekly dosages between 300 and 2000 mg, extra to the fact that co-administration of therapeutics to treat side-effects represent a routine procedure. Beside the most frequent use of medications used to treat erectile dysfunction or estrogenic side-effects, a substantial number of antihypertensive drugs of various classes, i.e. beta-blockers, diuretics, angiotensin II receptor antagonists, calcium channel blockers, as well as ACE inhibitors were recently confiscated in relevant doping cases. The presumptive correlation between misuse of anabolic steroids and self-treatment of cardiovascular side effects was explicitly confirmed by detailed user statements.Two representative fatalities of bodybuilders were introduced to outline characteristic, often lethal side effects of excessive steroid abuse. Moreover, illustrative autopsy findings of steroid acne, thrombotic occlusion of Ramus interventricularis anterior and signs of cardiac infarctions are presented.A potential steroid abuse should be carefully considered in cases of medical consultations of patients exhibiting apparent constitutional modifications and corresponding adverse effects. Moreover, common self-medications -as frequently applied by steroid consumers- should be taken into therapeutic considerations.
authors.affiliation: Institut für Dopinganalytik, Dresdner Str. 12, 01731, Kreischa, Deutschland, Detlef.Thieme@idas-kreischa.de.
authors.forename: D
authors.initials: D
authors.lastname: Thieme
authors.forename: A
authors.initials: A
authors.lastname: Büttner
mesh_terms: D045930:Anabolic Agents / Q000009:adverse effects*; D000728:Androgens / Q000009:adverse effects*; D004300:Doping in Sports / Q000379:methods / Q000517:prevention & control*; D006331:Heart Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control*; D006801:Humans; D058573:Performance-Enhancing Substances / Q000009:adverse effects*
chemical_list: D045930:Anabolic Agents; D000728:Androgens; D058573:Performance-Enhancing Substances
references.citation: Heart. 2004 May;90(5):496-501
references.pmid: 15084541
references.citation: AIDS Read. 2001 Mar;11(3):157-60
references.pmid: 17004353
references.citation: Prog Cardiovasc Dis. 1998 Jul-Aug;41(1):1-15
references.pmid: 9717856
references.citation: Eur J Appl Physiol Occup Physiol. 1989;59(1-2):98-103
references.pmid: 2583156
references.citation: J Am Coll Cardiol. 2001 Jan;37(1):224-30
references.pmid: 11153743
references.citation: Handb Exp Pharmacol. 2010;(195):459-84
references.pmid: 20020376
references.citation: J Clin Psychiatry. 2003 Feb;64(2):156-60
references.pmid: 12633124
references.citation: Med Sci Sports Exerc. 1995 Sep;27(9):1252-62
references.pmid: 8531623
references.citation: Heart. 2004 May;90(5):473-5
references.pmid: 15084526
references.citation: J Sports Med Phys Fitness. 1991 Dec;31(4):618-26
references.pmid: 1806744
references.citation: Arch Pathol Lab Med. 2001 Feb;125(2):253-5
references.pmid: 11175645
references.citation: N Engl J Med. 2000 May 18;342(20):1532
references.pmid: 10819660
references.citation: Med Sci Sports Exerc. 2006 Apr;38(4):644-51
references.pmid: 16679978
references.citation: J Forensic Sci. 2014 Jul;59(4):1025-8
references.pmid: 24611438
references.citation: Drug Alcohol Depend. 2011 Apr 1;114(2-3):100-9
references.pmid: 21232881
references.citation: Handb Exp Pharmacol. 2010;(195):411-57
references.pmid: 20020375
references.citation: Baillieres Best Pract Res Clin Endocrinol Metab. 2000 Mar;14(1):55-69
references.pmid: 10932810
references.citation: Cardiovasc Pathol. 2012 Jul-Aug;21(4):312-6
references.pmid: 22104006
references.citation: Int J Legal Med. 1998;111(5):261-4
references.pmid: 9728754
references.citation: Int J Sports Med. 2000 Aug;21(6):412-8
references.pmid: 10961516
references.citation: Forensic Sci Int. 2012 Apr 10;217(1-3):e13-8
references.pmid: 22047750
references.citation: Circ Heart Fail. 2010 Jul;3(4):472-6
references.pmid: 20424234
references.citation: J Forensic Sci. 2000 Jan;45(1):16-23
references.pmid: 10641914